Skip to main content
Equibles
KNSA logo

KNSA · Kiniksa Pharmaceuticals International, plc

Track KNSA — free

Use KNSA with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about KNSA

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$76.75 -1.08 (-1.39%) At close · Aug 14
Market Cap
$11.98B
Shares
156.05M

Kiniksa Pharmaceuticals International, plc Earnings Call Transcripts

Every quarterly earnings call for Kiniksa Pharmaceuticals International, plc (KNSA) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲719.6% $99.14M $224.09M '22 Q3 22-11-01 · $61.88M $4.46M '22 Q4 23-02-28 ▲50.2% $48.34M −$12.27M '23 Q1 23-05-02 ▲165% $71.47M $14.97M '23 Q2 23-07-25 ▼32.4% $67.05M −$13.86M '23 Q3 23-10-31 ▲34.8% $83.39M $25.24M '23 Q4 24-02-28 ▲65.2% $79.86M −$17.70M '24 Q1 24-04-23 ▲52% $108.63M −$3.91M '24 Q2 24-07-23 ▲67.4% $112.21M −$12.69M '24 Q3 24-10-29 ▲46.9% $122.54M −$8.89M '24 Q4 25-02-25 ▲72.5% $137.78M $8.54M '25 Q1 25-04-29 ▲44.3% $156.80M $17.83M '25 Q2 25-07-29 ▲61.2% $180.85M $18.43M '25 Q3 25-10-28 ▲65% $202.13M $14.20M '25 Q4 26-02-24 LATEST ▲55.5% $214.27M $22.59M '26 Q1 26-04-28
Earnings call
FY26 · Q2
2026-07-28
Kiniksa Pharmaceuticals International, plc Q2 FY2026 Earnings Call
Confident tone KPL-387 Phase 3 advancement ARCALIST commercial momentum ACC clinical guidelines dissemination
Results not yet reported
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-09
Goldman Sachs 47th Annual Global Healthcare Conference
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-06-03
2026 Jefferies Global Healthcare Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-04-28
Kiniksa Pharmaceuticals International, plc Q1 FY2026 Earnings Call
Revenue
$214.27M
▲ 55.5% YoY
Diluted EPS
$0.27
▲ 145.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-24
Kiniksa Pharmaceuticals International, plc Q4 FY2025 Earnings Call
Confident tone ARCALYST commercial growth KPL-387 pipeline development KPL-1161 early pipeline
Revenue
$202.13M*
▲ 65% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-10-28
Kiniksa Pharmaceuticals International, plc Q3 FY2025 Earnings Call
Confident tone Patient Adherence and Duration of Therapy ARCALYST Commercial Growth Recurrent Pericarditis Market Penetration
Revenue
$180.85M
▲ 61.2% YoY
Diluted EPS
$0.23
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-07-29
Kiniksa Pharmaceuticals International, plc Q2 FY2025 Earnings Call
Confident tone ARCALYST commercial execution KPL-387 pipeline (recurrent pericarditis) Recurrent pericarditis market leadership
Revenue
$156.80M
▲ 44.3% YoY
Diluted EPS
$0.23
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-04-29
Kiniksa Pharmaceuticals International, plc Q1 FY2025 Earnings Call
Confident tone ARCALYST commercial performance and guidance raise KPL-387 pipeline development in recurrent pericarditis Medicare Part D / IRA affordability changes
Revenue
$137.78M
▲ 72.5% YoY
Diluted EPS
$0.11
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-25
Kiniksa Pharmaceuticals International, plc Q4 FY2024 Earnings Call
Confident tone KPL-387 program announcement ARCALYST commercial growth Pipeline portfolio prioritization
Revenue
$122.54M*
▲ 46.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-10-29
Kiniksa Pharmaceuticals International, plc Q3 FY2024 Earnings Call
Confident tone ARCALYST commercial execution First recurrence (earlier-line) prescribing Abiprubart pipeline in Sjogren's disease
Revenue
$112.21M
▲ 67.4% YoY
Diluted EPS
$-0.18
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-07-23
Kiniksa Pharmaceuticals International, plc Q2 FY2024 Earnings Call
Confident tone ARCALYST commercial performance Abiprubart pipeline / Sjögren's Phase 2b Guidance and outlook
Revenue
$108.63M
▲ 52% YoY
Diluted EPS
$-0.06
▼ 128.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-04-23
Kiniksa Pharmaceuticals International, plc Q1 FY2024 Earnings Call
Confident tone ARCALYST commercial performance Abiprubart pipeline / Sjögren's Disease RESONANCE Registry and steroid-sparing paradigm
Revenue
$79.86M
▲ 65.2% YoY
Diluted EPS
$-0.25
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-28
Kiniksa Pharmaceuticals International, plc Q4 FY2023 Earnings Call
Confident tone ARCALYST commercial performance Abiprubart Phase II clinical data Abiprubart Phase IIb in new indication
Revenue
$83.39M*
▲ 34.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-10-31
Kiniksa Pharmaceuticals International, plc Q3 FY2023 Earnings Call
Revenue
$67.05M
▼ 32.4% YoY
Diluted EPS
$-0.20
▼ 106.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-07-25
Kiniksa Pharmaceuticals International, plc Q2 FY2023 Earnings Call
Revenue
$71.47M
▲ 165% YoY
Diluted EPS
$0.21
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-02
Kiniksa Pharmaceuticals International, plc Q1 FY2023 Earnings Call
Revenue
$48.34M
▲ 50.2% YoY
Diluted EPS
$-0.18
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-02-28
Kiniksa Pharmaceuticals International, plc Q4 FY2022 Earnings Call
Revenue
$61.88M*
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-01
Kiniksa Pharmaceuticals International, plc Q3 FY2022 Earnings Call
Revenue
$99.14M
▲ 719.6% YoY
Diluted EPS
$3.18
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-03
Kiniksa Pharmaceuticals International, plc Q2 FY2022 Earnings Call
Revenue
$26.97M
▲ 250.1% YoY
Diluted EPS
$-0.29
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-03
Kiniksa Pharmaceuticals International, plc Q1 FY2022 Earnings Call
Revenue
$32.19M
Diluted EPS
$-0.36
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-22
Kiniksa Pharmaceuticals International, plc Q4 FY2021 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-01
Kiniksa Pharmaceuticals International, plc Q3 FY2021 Earnings Call
Revenue
$12.10M
Diluted EPS
$-0.44
Rev · 2q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-03
Kiniksa Pharmaceuticals International, plc Q2 FY2021 Earnings Call
Revenue
$7.70M
Diluted EPS
$-0.61
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-01-13
Kiniksa Pharmaceuticals International, plc Q4 FY2019 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Showing 1–24 of 24 earnings calls
Key facts CIK 1730430 CUSIP G52694109 13F (30d) 257 filings 254 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)